Month: February 2022

Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma

02/14/2022

Broad, durable, and systemic anti-tumor immunity observed using inCPMV with OX40 agonist antibodies Intratumoral inCPMV administration in combination with systemic anti-OX40 controlled the progression of the primary as well as secondary untreated tumors 70% of animals survived for at least 100 days post tumor challenge without development of recurrence or metastatic disease Excerpt from the…

Read More

AARDVARK THERAPEUTICS, INC., ANNOUNCES THE INITIATION OF ENROLLMENT FOR THREE PHASE 2 CLINICAL TRIALS OF ORAL ARD-101

02/14/2022

– Two studies evaluate ARD-101 in Obesity: one in General Obesity and the other in Refractory Weight Gain Post-Bariatric Surgery – The 3rd clinical trial is in Prader-Willi Syndrome, a rare genetic disorder characterized by persistent hyperphagia Excerpt from the Press Release: SAN DIEGO, Feb. 2, 2022 /PRNewswire/ — Aardvark Therapeutics, Inc., a clinical stage biopharmaceutical company focused…

Read More

Oncolytics Biotech® Provides Positive Safety Update on the Pancreatic Cancer Cohort of its Multi-Indication Phase 1/2 Gastrointestinal Cancer Trial

02/14/2022

Excerpt from the Press Release: Independent safety review completed with no toxicity concerns Cohort builds on prior proof-of-concept data demonstrating clinical benefit of pelareorep-checkpoint inhibitor combination in pancreatic cancer Multi-indication trial being conducted in collaboration with Roche and AIO also includes cohorts in metastatic colorectal and advanced anal cancers SAN DIEGO and CALGARY, AB, Feb. 2, 2022 /PRNewswire/ — Oncolytics…

Read More

UroGen Announces Start of Pivotal Single-Arm Phase 3 Trial for UGN-102, an Investigational Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

02/11/2022

— ENVISION Study Design Similar to Successful UGN-102 Phase 2b OPTIMA II Trial — Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat urothelial and specialty cancers, today announced the initiation of its Phase 3 ENVISION study of UGN-102 (mitomycin)…

Read More

T2 Biosystems T2SARS-CoV-2™ Panel Detects Omicron Subvariants

02/11/2022

Excerpt from the Press Release: LEXINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO),  a leader in the rapid detection of sepsis-causing pathogens, today announced that its T2SARS-CoV-2™ Panel detects Omicron COVID-19 subvariants BA.1, BA.2, and BA.3. According to the Centers for Disease Control and Prevention, the Omicron variant of the SARS-CoV-2 virus…

Read More

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

02/11/2022

Excerpt from the Press Release: ZUG, Switzerland, and CAMBRIDGE, Mass., and SAN DIEGO, Calif., February 2, 2022 – CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, and ViaCyte, Inc., a clinical-stage regenerative medicine company developing novel cell replacement therapies to address diseases with significant unmet needs, today…

Read More

Pardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 Infections

02/10/2022

CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associated diseases (i.e., COVID-19), today announced that its Investigational New Drug (IND) application for PBI-0451 has been cleared…

Read More

Synthekine Doses First Patient in Phase 1 Clinical Trial of IL-2 Partial Agonist, STK-012, for Treatment of Solid Tumors

02/10/2022

Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Synthekine Inc., an engineered cytokine therapeutics company, today announced the dosing of the first patient in a Phase 1a/1b clinical trial of its IL-2 partial agonist, STK-012, for the treatment of solid tumors. STK-012 is designed as an alpha/beta-biased IL-2 partial agonist to selectively stimulate antigen-activated T…

Read More

Kodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

02/10/2022

– Over 900 patients with diabetic macular edema enrolled worldwide Excerpt from the Press Release: PALO ALTO, Calif., Feb. 3, 2022 /PRNewswire/ — Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in its GLEAM and GLIMMER Phase 3…

Read More

CHOP Researchers Use Deep Learning to Find Genetic Causes of Mental Health Disorders in Frequently Understudied African American Population

02/09/2022

–The method could eventually lead to more personalized medicine approaches as well as properly diagnose patients with multiple disorders — Excerpt from the Press Release: PHILADELPHIA, Feb. 1, 2022 /PRNewswire/ –Minority populations have been historically under-represented in existing studies addressing how genetic variations may contribute to a variety of disorders. A new study from researchers at Children’s Hospital…

Read More